NO20085217L - Effektive pyrimidinderivater i behandlingen av kreft - Google Patents

Effektive pyrimidinderivater i behandlingen av kreft

Info

Publication number
NO20085217L
NO20085217L NO20085217A NO20085217A NO20085217L NO 20085217 L NO20085217 L NO 20085217L NO 20085217 A NO20085217 A NO 20085217A NO 20085217 A NO20085217 A NO 20085217A NO 20085217 L NO20085217 L NO 20085217L
Authority
NO
Norway
Prior art keywords
cancer
effective
treatment
pyrimidine derivatives
pyrimidine
Prior art date
Application number
NO20085217A
Other languages
English (en)
Inventor
Thorsten Nowak
Andrew Peter Thomas
David Buttar
Kevin Michael Foote
David Alan Rudge
Maria-Elena Theoclitou
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20085217L publication Critical patent/NO20085217L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det tilveiebringes en forbindelse med formel (I): (I) prosesser for fremstilling av denne, farmasøytiske preparater derav og anvendelse i terapi.
NO20085217A 2006-06-30 2008-12-15 Effektive pyrimidinderivater i behandlingen av kreft NO20085217L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81825906P 2006-06-30 2006-06-30
US90842807P 2007-03-28 2007-03-28
PCT/GB2007/002381 WO2008001070A1 (en) 2006-06-30 2007-06-27 Pyrimidine derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20085217L true NO20085217L (no) 2009-01-12

Family

ID=38472858

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085217A NO20085217L (no) 2006-06-30 2008-12-15 Effektive pyrimidinderivater i behandlingen av kreft

Country Status (13)

Country Link
US (1) US20080004302A1 (no)
EP (1) EP2044063A1 (no)
JP (1) JP2009541480A (no)
KR (1) KR20090024270A (no)
AR (1) AR061737A1 (no)
AU (1) AU2007263655A1 (no)
CA (1) CA2654852A1 (no)
IL (1) IL195731A0 (no)
MX (1) MX2008016523A (no)
NO (1) NO20085217L (no)
TW (1) TW200817391A (no)
UY (1) UY30444A1 (no)
WO (1) WO2008001070A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
DK2383268T3 (en) * 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
KR101362621B1 (ko) * 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
CA2608009A1 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0618011A2 (pt) * 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
MX2010013682A (es) * 2008-06-11 2011-03-15 Astrazeneca Ab Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
WO2010005692A2 (en) * 2008-06-16 2010-01-14 E. I. Du Pont De Nemours And Company Insecticidal cyclic carbonyl amidines
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式ｊａｋキナーゼ阻害剤
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
AU2010250923A1 (en) 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
JP2012102088A (ja) * 2010-10-14 2012-05-31 Sumitomo Chemical Co Ltd ヘテロ芳香環化合物およびその有害生物防除用途
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
JP2014525418A (ja) * 2011-09-05 2014-09-29 浙江海正薬業股▲ふん▼有限公司 タンパク質キナーゼ阻害活性を有する４−置換−（３−置換−１ｈ−ピラゾール−５−アミノ）−ピリミジン誘導体及びその使用
CA2871589C (en) 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP6183053B2 (ja) * 2012-08-22 2017-08-23 宇部興産株式会社 テトラヒドロピラニルピリミジン化合物の製造方法
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2931460T3 (es) * 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
AU2018208366B2 (en) 2017-01-10 2020-12-17 National Health Research Institutes Heterocyclic compounds and use thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
CN110143939A (zh) * 2019-05-07 2019-08-20 中国科学技术大学 一种由呋喃醛基化合物制备呋喃丙烯酸酯的方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
TW202402288A (zh) 2022-05-26 2024-01-16 義大利商Ｔｅｓ製藥（股份）責任有限公司 用於治療急性炎症之嘧啶酮化合物
CN115466234B (zh) * 2022-10-25 2024-01-30 安徽华业香料股份有限公司 一种γ-庚内酯的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
ES2328820T3 (es) * 2003-10-17 2009-11-18 Astrazeneca Ab Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US8211929B2 (en) * 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use

Also Published As

Publication number Publication date
US20080004302A1 (en) 2008-01-03
AU2007263655A1 (en) 2008-01-03
WO2008001070A1 (en) 2008-01-03
JP2009541480A (ja) 2009-11-26
TW200817391A (en) 2008-04-16
CA2654852A1 (en) 2008-01-03
KR20090024270A (ko) 2009-03-06
MX2008016523A (es) 2009-01-19
EP2044063A1 (en) 2009-04-08
AR061737A1 (es) 2008-09-17
IL195731A0 (en) 2009-09-01
UY30444A1 (es) 2008-01-31

Similar Documents

Publication Publication Date Title
NO20092033L (no) Nye forbindelser
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
NO20090878L (no) Smac peptidoetterligninger nyttige som IAP-inhibitorer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20090628L (no) Pyridizinon derivativater
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application